CardioSource WorldNews | Page 31

When asked by CSWN, he too agreed that “Stroke is only one effect of AF on the brain—another is dementia. AF also increases hospitalizations, increases heart failure, increases mortality, etc. Thus, preventing stroke is only one aspect of AF care, but it is a very important element of care.” Indeed, if a University of Minnesota study is correct, the cognitive decline in people with AF is mediated by subclinical cerebral infarcts (SCIs) as detected by magnetic resonance imaging. The study was led by Lin Yee Chen, MD, a University of Minnesota cardiologist who analyzed 935 participants of the Atherosclerosis Risk in Communities Study.16 Among participants without SCIs on MRI scans, incident AF was not associated with cognitive decline. In contrast, incident AF was associated with greater annual average rate of decline in word fluency (p = 0.002) among participants with prevalent SCIs “Our findings have important clinical and public health implications,” he said. “They raise the possibility of anticoagulation as a strategy to prevent cognitive decline in patients with AF.” Protecting the Brain Despite available data, the need looms large for sizable multicenter studies to examine the effects of NOACs, rhythm and rate control, and left atrial appendage occlusion on long-term cognitive function. Heart rate may be important because Bunch et al. have found a linear, and inverse risk association with heart rate and dementia with lower heart rates increasing dementia risk. The Utah team is planning a randomized trial of pacing rates and their effect on cognition. Also, they will do further work in evaluating a genetic marker that tracks for early-onset AF and stroke and those patients who have very high dementia rates. Until large multicenter and randomized clinical trial data are completed, what can be done now to save the brain? According to Dr. Prystowsky, one way to lower stroke risk and better protect the brain: assess risk using the broader CHA2DS2-VASc risk assessment tool (a Class I recommendation in the current ACC/AHA guidelines).17 With prior stroke, TIA, or a CHA2DS2-VASc score > 2, oral anticoagulants are recommended (Class I recommendation) based on shared decision making, with a discussion of the risk of stroke and bleeding that considers patient preferences (also a Class I recommendation). “In my own experience,” said Dr. Prystowsky, “it takes about 10 minutes to go over this with my patients. It’s a very important decision that is well worth the time and then you make a shared decision.” Dr. Bunch said he is trying to reinforce that warfarin is safe if it’s managed well. As a participant in the pivotal trial for rivaroxaban and a member of that trial’s stroke advisory committee, Dr. Bunch said some clinics put people on warfarin for the first time and then didn’t check their INR until 4–5 weeks later. That approach, he said, is “exposing people to crazy ranges of therapeutic. As a community that uses warfarin, we have to get away from those practices.” Catheter ablation is emerging as an effective alternative to maintain patients in sinus rhythm. Short term, AF ablation seems to increase postoperative ACC.org/CSWN cognitive dysfunction; it’s detectable in 24% of patients at day 2 and 13% at 90 days.18 However, in the longer term, ablation shows promise for decreasing the risk of all types of dementia.19 Besides maintaining sinus rhythm and oral anticoagulation, there is also evidence that aggressive risk factor modification may reduce the likelihood or delay the onset of dementia.20 Dr. Bunch said the risk for dementia among all AF patients is lowest among his patients treated with catheter ablation who maintain sinus rhythm long term. Yes, the low rates of dementia likely reflect healthier patients selected for ablation, the complex system of catheter ablation, and resulting follow-up care. Nevertheless, Dr. Bunch suspect that it also reflects cessation of long-term anticoagulation exposure, improving cardiac output, and minimizing beat-to-beat variability in some low-risk patients. Dr. Bunch said he and his team get e-mails from all over the world wondering about effective therapeutic strategies and their first message is always, “If you have